<DOC>
	<DOCNO>NCT01681290</DOCNO>
	<brief_summary>The purpose study determine beneficial effect CBX129801 ( PEGylated synthetic human C-peptide ) follow weekly subcutaneous administration 12 month type 1 diabetes mellitus patient ( T1DM ) mild moderate diabetic peripheral neuropathy ( DPN ) .</brief_summary>
	<brief_title>Safety Efficacy CBX129801 Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Key Give informed consent ; 1865 year old ; Have type 1 diabetes mellitus minimum 5 year , stable diabetic regimen ( least 3 month ) ; Have clinical sign diabetic peripheral neuropathy screening ; Have abnormal sural nerve conduction observe bilaterally screen ; Be Cpeptide deficient ; Be good general health ( besides type 1 diabetes mellitus ) ; Practice effective contraception least 12 week study participation ; Have body mass index ( BMI ) ≥18.0 &lt; 35.0 kg/m2 . Key Any significant cardiovascular , hematological , lymphatic , immunologic , urologic , dermatologic , psychiatric , renal , hepatic , pulmonary , endocrine ( except diabetes mellitus ) , central nervous , gastrointestinal , major disease ; Unstable inadequate glucose control ; Any clinically significant laboratory value screening ; Occurrence severe , unexplainable hypoglycemic event ( define require assistance another individual ) within 6 month Day 0 , recurrent episode nonsevere hypoglycemia ( ≥3 per week average ) deem clinically significant Investigator ; Have islet cell , kidney , and/or pancreas transplant ; If female , pregnant lactating ; History alcohol substance abuse within 2 year ; Positive screen hepatitis B , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody ; Initiation treatment change dose medication could affect peripheral nerve function within 60 day ; Previous treatment CBX129801 unmodified Cpeptide ; Receipt investigational product therapeutic device , participation drug research study , within period 30 day ; Chronic use oral steroid use Ampyra ( dalfampridine ) within 60 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>